New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
07:02 EDTSLXPSalix announces outcome for TARGET 3 study evaluating rifaximin
Salix Pharmaceuticals announced the "successful" outcome of TARGET 3, a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg TID for 14 days in subjects with irritable bowel syndrome with diarrhea, or IBS-D, who respond to an initial treatment course with rifaximin 550 mg TID for 14 days. In the study a statistically significant greater proportion of rifaximin treated subjects responded to repeat treatment as assessed by the composite primary endpoint of IBS-related abdominal pain and stool consistency during the 4 week treatment-free follow-up period in the Double Blind Repeat Treatment Phase. The company said, "The outcome of TARGET 3 serves to corroborate the results of TARGET 1 and TARGET 2, the confirmatory Phase 3 trials for our supplemental New Drug Application seeking marketing approval for rifaximin as a treatment option for irritable bowel syndrome with diarrhea.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
17:19 EDTSLXPCNO Financial to replace Salix Pharmaceuticals in S&P 400 as of 4/6 close
Subscribe for More Information
16:27 EDTSLXPSalix Pharmaceuticals requests withdrawal of registration statement
Subscribe for More Information
06:07 EDTSLXPValeant completes tender offer for Salix
Subscribe for More Information
06:05 EDTSLXPValeant Pharmaceuticals International completes tender offer for Salix
Subscribe for More Information
March 26, 2015
10:45 EDTSLXPSynergy discussing possible sale with advisers, Bloomberg reports
Subscribe for More Information
March 25, 2015
12:58 EDTSLXPPershing Square raises stake in Valeant, says will discuss acquisitions
Subscribe for More Information
10:51 EDTSLXPOptions with increasing implied volatility
Options with increasing implied volatility: CLDN CMG CREE AMZN ISRG MAC UA VMW SLXP
March 20, 2015
16:33 EDTSLXPStocks end week higher after market reads Fed statement as dovish
Subscribe for More Information
10:18 EDTSLXPOptions with decreasing implied volatility
Options with decreasing implied volatility: NKTR FOLD RUSL RSX ORCL GES CTRP SLXP WSM SPXS
March 19, 2015
10:42 EDTSLXPOptions with decreasing implied volatility
Subscribe for More Information
March 18, 2015
10:00 EDTSLXPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:45 EDTSLXPSalix downgraded to Hold from Buy at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use